Director/PDMR Shareholding
Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Issue of shares in lieu of salary,
Director / PDMR shareholdings &
Total voting rights
Oxford, UK - 29 November 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform, announces the issue of 2,435,178 ordinary shares of 1 pence each ("Ordinary Shares") at a price of 1.25 per share (the "New Ordinary Shares") to its directors, PDMRs and certain other senior staff members to satisfy part of their salaries and fees, in line with the Company's ongoing strategy to preserve its cash resources as announced on 14 October 2024. The issue price is equal to the closing market price of the Company's Ordinary Shares on 27 November 2024, being the last practicable date prior to the issue of the New Ordinary Shares.
The New Ordinary Shares being issued have been allocated to the following directors and PDMRs:
Director / PDMR | Position | Number of New Ordinary Shares issued | Resultant shareholding in the Company | % of the issued share capital of the Company |
Dr Jon Burrows | Chief Executive Officer | 524,604 | 2,106,174 | 0.67% |
Dr Alexandre Akoulitchev | Chief Scientific Officer | 202,034 | 7,332,712 | 2.32% |
Paul Stockdale | Chief Financial Officer | 187,041 | 865,372 | 0.27% |
Matthew Wakefield | Non-Executive Chairman | 102,043 | 1,500,665 | 0.47% |
Dr David Holbrook | Non-Executive Director | 51,640 | 101,293 | 0.03% |
Thomas Guiel | Chief Operating Officer | 218,370 | 1,026,803 | 0.32% |
Dr Ewan Hunter | Chief Data Officer | 171,353 | 528,034 | 0.17% |
Application will be made for the New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur at 8.00 a.m. on or around 5 December 2024. The New Ordinary Shares have been issued as fully paid and rank pari passu in all respects with the existing Ordinary Shares.
Following Admission, the Company's issued share capital will consist of 316,576,569 Ordinary Shares. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 316,576,569 and this figure may be used by Shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Further details of the PDMR dealings are included below. This information has been provided in accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
-Ends-
For more information:
Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO
| +44 (0)1865 518910 |
Shore Capital Stephane Auton Lucy Bowden
| +44 (0)20 7408 4090 |
WG Partners (Joint Broker to OBD) David Wilson / Claes Spång /
| +44 (0)20 3705 9330 |
Vigo Consulting
| +44 (0)20 7390 0230 obd@vigoconsulting.com
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.
Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
The notifications below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||||||||||||||||||||
a)
| Name
| 1) Dr Jon Burrows 2) Dr Alexandre Akoulitchev 3) Paul Stockdale 4) Matthew Wakefield 5) Dr David Holbrook 6) Thomas Guiel 7) Dr Ewan Hunter
| ||||||||||||||||||||||||
2
| Reason for the notification
| |||||||||||||||||||||||||
a)
| Position/status
| 1) Chief Executive Officer, Director 2) Chief Scientific Officer, Director 3) Chief Financial Officer, Director 4) Non-Executive Director 5) Non-Executive Director 6) Chief Operating Officer, PDMR 7) Chief Data Officer, PDMR | ||||||||||||||||||||||||
b)
| Initial notification /Amendment
| Initial notification | ||||||||||||||||||||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||||||||||||||||||||
a)
| Name
| Oxford Biodynamics plc | ||||||||||||||||||||||||
b)
| LEI
| 2138005Y1TK258O5U928 | ||||||||||||||||||||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||||||||||||||||||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares
ISIN: GB00BD5H8572 | ||||||||||||||||||||||||
b)
| Nature of the transaction
| Issue of New Ordinary Shares in lieu of salary | ||||||||||||||||||||||||
c)
| Price(s) and volume(s) |
| ||||||||||||||||||||||||
d)
| Aggregated information
- Aggregated volume
- Price
|
N/A - single transactions | ||||||||||||||||||||||||
e)
| Date of the transaction
| 28 November 2024 | ||||||||||||||||||||||||
f) | Place of the transaction | London Stock Exchange (XLON) |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.